Delving into the Latest Updates on Tokyo Metropolitan Komagome Hospital with Synapse

This is a phase 2 trial of foscenvivint in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia to evaluate the efficacy, safety and pharmacokinetics.

开始日期2024-05-08

申办/合作机构

Tokyo Metropolitan Komagome Hospital

[+1]

NCT04688034 / Completed临床1期IIT

Phase I Clinical Trial of CBP/Beta-catenin Inhibitor OP-724 in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection with Hemophilia. (OP-724-H101)

To evaluate the safety and tolerability of OP-724 in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia.

开始日期2021-03-15

申办/合作机构

Tokyo Metropolitan Komagome Hospital

[+2]

NCT04047160 / Completed临床1期IIT

An Open-Label, Dose-Finding Study for the CBP / β-catenin Inhibitor OP-724 in Patients With Primary Biliary Cholangitis (Phase I)

To evaluate the safety and pharmacokinetics of OP-724 and to determine the recommended dose of OP-724 against Primary Biliary Cholangitis patients.

开始日期2019-08-29

申办/合作机构

Tokyo Metropolitan Komagome Hospital

[+2]

100 项与 Tokyo Metropolitan Komagome Hospital 相关的临床结果

登录后查看更多信息

0 项与 Tokyo Metropolitan Komagome Hospital 相关的专利（医药）

登录后查看更多信息

2,884

项与 Tokyo Metropolitan Komagome Hospital 相关的文献（医药）

2025-03-01·Infectious Disease Modelling

Regional variations in HIV diagnosis in Japan before and during the COVID-19 pandemic

Article

作者: Fujiwara, Seiko ; Nishiura, Hiroshi ; Shirasaka, Takuma ; Imamura, Akifumi

BackgroundThe number of people undergoing voluntary HIV testing has abruptly decreased since 2020. The geographical heterogeneity of HIV infection and the impact of COVID-19 on the diagnosis of HIV at regional level are important to understand. This study aimed to estimate the HIV incidence by geographical region and understand how the COVID-19 pandemic influenced diagnosis of HIV.MethodsWe used an extended back-calculation method to reconstruct the epidemiological dynamics of HIV/AIDS by geographical region. We used eight regions: Tokyo, the capital of Japan, Hokkaido plus Tohoku, Kanto plus Koshinetsu (excluding Tokyo), Hokuriku, Tokai, Kinki, Chugoku plus Shikoku, and Kyushu plus Okinawa. Four different epidemiological measurements were evaluated: (i) estimated HIV incidence, (ii) estimated rate of diagnosis, (iii) number of undiagnosed HIV infections, and (iv) proportion of HIV infections that had been diagnosed.ResultsThe incidence of HIV/AIDS during the COVID-19 pandemic from 2020 to 2022 increased in all regions except Kanto/Koshinetsu (51.3 cases/year), Tokyo (183.9 cases/year), Hokuriku (1.0 cases/year), and Tokai (43.1 cases/year). The proportion of HIV infections that had been diagnosed only exceeded 90% in Tokyo (91.7%, 95% confidence interval (CI): 90.6, 93.3), Kanto/Koshinetsu (91.0%, 95% CI: 87.3, 97.8), and Kinki (92.5%, 95% CI: 90.4, 95.9). The proportion of infections that had been diagnosed was estimated at 83.3% (95% CI: 75.1, 98.7) in Chugoku/Shikoku and 80.5% (95% CI: 73.9, 91.0) in Kyusyu/Okinawa.ConclusionsIn urban regions with major metropolitan cities, including Tokyo, Kinki, and Kanto/Koshinetsu, the number of undiagnosed HIV infections is substantial. However, the proportion of undiagnosed infections was estimated to be smaller than in other regions. The diagnosed proportion was the lowest in Kyusyu/Okinawa (80.5%), followed by Chugoku/Shikoku and Hokkaido/Tohoku. The level of diagnosis in those regional prefectures may have been more influenced and damaged by the COVID-19 pandemic than in urban settings.

2024-12-31·OncoImmunology

Candidate tumor-specific CD8 ⁺ T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis

Article

作者: Sugita, Yusuke ; Horio, Yoshitsugu ; Clancy, Trevor ; Yamashita, Yoshiko ; Muraoka, Daisuke ; Ishibashi, Hironori ; Demachi-Okamura, Ayako ; Yamaguchi, Rui ; Komuro, Hiroyasu ; Tanaka, Yuki ; Kuroda, Hiroaki ; Matsui, Takuya ; Onoue, Kousuke ; Hashimoto, Kana ; Shinohara, Shuichi ; Sasaki, Eiichi ; Masago, Katsuhiro ; Matsushita, Hirokazu ; Miura, Daiki ; Hamana, Hiroshi ; Takashima, Chieko ; Onoguchi, Kazuhide ; Takahashi, Yusuke ; Tanaka, Ichidai ; Kishi, Hiroyuki ; Okubo, Kenichi ; Yamaguchi, Teppei ; Fukushima, Yasunori ; Nishida, Reina ; Stratford, Richard

Isolation of tumor-specific T cells and their antigen receptors (TCRs) from malignant pleural effusions (MPE) may facilitate the development of TCR-transduced adoptive cellular immunotherapy products for advanced lung cancer patients. However, the characteristics and markers of tumor-specific T-cells in MPE are largely undefined. To this end, to establish the phenotypes and antigen specificities of CD8⁺ T cells, we performed single-cell RNA and TCR sequencing of samples from three advanced lung cancer patients. Dimensionality reduction on a total of 4,983 CD8⁺ T cells revealed 10 clusters including naïve, memory, and exhausted phenotypes. We focused particularly on exhausted T cell clusters and tested their TCR reactivity against neoantigens predicted from autologous cancer cell lines. Four different TCRs specific for the same neoantigen and one orphan TCR specific for the autologous cell line were identified from one of the patients. Differential gene expression analysis in tumor-specific T cells relative to the other T cells identified CXCL13, as a candidate gene expressed by tumor-specific T cells. In addition to expressing CXCL13, tumor-specific T cells were present in a higher proportion of T cells co-expressing PDCD1(PD-1)/TNFRSF9(4-1BB). Furthermore, flow cytometric analyses in advanced lung cancer patients with MPE documented that those with high PD-1/4-1BB expression have a better prognosis in the subset of 57 adenocarcinoma patients (p = .039). These data suggest that PD-1/4-1BB co-expression might identify tumor-specific CD8⁺ T cells in MPE, which are associated with patients' prognosis. (233 words).

2024-10-08·Neurology

Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML

Article

作者: Mori, Koichiro ; Matsuda, Toshiya ; Nakamichi, Kazuo ; Yokote, Hiroaki ; Miura, Yoshiharu

100 项与 Tokyo Metropolitan Komagome Hospital 相关的药物交易

登录后查看更多信息

100 项与 Tokyo Metropolitan Komagome Hospital 相关的转化医学

登录后查看更多信息